Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes Empagliflozin May Reduce LV Mass in Patients With CVD, Diabetes
EMPA-HEART Cardiolink-6 trial results suggest that the SGLT2 inhibitor is linked to reduced left ventricular mass, a surrogate for reduced heart failure, in patients with CVD and type 2 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 13, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Study suggests diabetes medication improves heart structure
(St. Michael's Hospital) The diabetes medication empagliflozin has important effects that can improve cardiac structure in people with Type 2 diabetes who also have heart disease, suggests a new study led by St. Michael's Hospital. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 12, 2018 Category: International Medicine & Public Health Source Type: news

AHA: Reverse Remodeling Plays Role in Jardiance CV Benefit
(MedPage Today) -- Data show empagliflozin-associated LV remodeling (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - November 11, 2018 Category: Pediatrics Source Type: news

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for hospitalisation for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease
Empagliflozin was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors1Effect of empagliflozin on HHF was consistent in patients with and without established cardiovascular disease1Findings support data from the landmark EMPA-REG OUTCOME ® trial, in which empagliflozin reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease2 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 5, 2018 Category: Research Source Type: news

Individual stress susceptibility and glucose metabolism are linked to brain function
(Johannes Gutenberg Universitaet Mainz) Researchers at the Department for Psychiatry and Psychotherapy at the Mainz University Medical Center and the German Resilience Center (DRZ) in Mainz have now discovered that stress-induced mental disturbances in mice are directly linked to abnormal glucose metabolism. Normalizing the stress-induced alterations in glucose levels, using the anti-diabetic drug empagliflozin, restored spatial memory as well as long-term glucose metabolism. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 24, 2018 Category: International Medicine & Public Health Source Type: news

EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk EASE: Empagliflozin Beneficial in Type 1 Diabetes, DKA a Risk
Speakers at EASD present divergent risk-benefit analyses for use of SGLT2 inhibitors in type 1 diabetes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 11, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
All investigated doses met the primary efficacy endpoint defined as a change from baseline in A1C versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results pr... Biopharmaceuticals, Endocrinology Boehringer Ingelheim, Eli Lilly, empagliflozin, EASE-2 study, diabetes (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - October 4, 2018 Category: Pharmaceuticals Source Type: news

Empa T1D Full Data
Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to insulin in type 1 diabetesAll investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment  Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes  Full results presented at the 54th European Association for the Study of Diabetes Annual Congress (EASD) and published online in Diabetes Care ahead of print1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 4, 2018 Category: Research Source Type: news

Empa long-term survival benefit
New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular diseaseSurvival estimates from the EMPA-REG OUTCOME ® trial data demonstrate potential long-term benefit of empagliflozin (marketed as Jardiance®) on life expectancy of adults with type 2 diabetes and cardiovascular disease1 (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 25, 2018 Category: Research Source Type: news

How One Class Of Diabetes Medications May Lead To Flesh-Eating Genital Infections
If you are taking canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, or any other sodium-glucose cotransporter-2 (SGLT2) inhibitor, you may want to pay attention to this FDA warning. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - September 1, 2018 Category: Pharmaceuticals Authors: Bruce Y. Lee, Contributor Source Type: news

Empagliflozin Doesn't Up Risk of Bone Fractures
FRIDAY, July 20, 2018 -- Empagliflozin does not increase the risk of bone fracture in patients with type 2 diabetes, according to a study published online June 15 in Diabetes Care. Sven Kohler, M.D., from Boehringer Ingelheim International in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2018 Category: Pharmaceuticals Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 10, 2018 Category: American Health Authors: Paul J. Gough Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 10, 2018 Category: Biotechnology Authors: Paul J. Gough Source Type: news

Highmark, pharmaceutical company reach deal on diabetes drug
Jardiance is prescribed for people with latter stages of Type 2 diabetes that also have cardiovascular disease. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - July 10, 2018 Category: American Health Authors: Paul J. Gough Source Type: news

Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients Lilly's Jardiance Meets Main Goal in Type 1 Diabetes Patients
Eli Lilly& Co said on Monday that its drug Jardiance (empagliflozin), along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes, a population for which it is not presently approved.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 25, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Lilly's Jardiance meets main goal of two diabetes trials
(Reuters) - Eli Lilly& Co said on Monday that its drug Jardiance, along with insulin therapy, met the main goal of two trials testing it in patients with type 1 diabetes. (Source: Reuters: Health)
Source: Reuters: Health - June 25, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Empagliflozin cost effective for T2D + CV disease in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

Novo Nordisk oral diabetes drug outperforms Lilly rival
The company's oral diabetes drug semaglutide was found to be better at lowering blood sugar levels than Jardiance from Eli Lilly and Boehringer Ingelheim (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - May 29, 2018 Category: Pharmaceuticals Source Type: news

Novo Nordisk's oral diabetes drug beats Jardiance in study
LONDON (Reuters) - An experimental diabetes pill from Novo Nordisk proved better at lowering blood sugar levels than Eli Lilly and Boehringer Ingelheim's established Jardiance in a clinical study, the Danish drugmaker said on Tuesday. (Source: Reuters: Health)
Source: Reuters: Health - May 29, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) have announced an academic collaboration with the University of Oxford. EMPA-KIDNEY will investigate the effects of empagliflozin on the progression of kidney disease and the occurrence of cardiovascular death, in people with established chronic kidney disease with and without diabetes. (Source: World Pharma News)
Source: World Pharma News - April 16, 2018 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD Empagliflozin Trims Liver Fat in Patients With T2D and NAFLD
Dr Kuchay discusses his findings from the E-LIFT study.Endocrine Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 9, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology Commentary Source Type: news

Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes Empagliflozin Eyed for Fatty Liver Disease in Type 2 Diabetes
The first trial of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes and nonalcoholic fatty liver disease indicates the drug might reduce liver fat, but the results of the small study need replication.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop? Empagliflozin Survival Benefit in Diabetes: Is it Plasma Volume Drop?
Changes in hematocrit and hemoglobin accounted for half the effect on CV death seen with empagliflozin in patients with type 2 diabetes in EMPA-REG Outcome, a new analysis confirms.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Empagliflozin good value for money for T2DM in Greece
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2018 Category: Drugs & Pharmacology Source Type: news

Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug
Boehringer Ingelheim has inked an outcomes-based contract with pharmacy benefit manager Prime Therapeutics for its oral Type II diabetes drug, Jardiance. The medication is designed to cut the risk of cardiovascular death in adult patients with Type II diabetes and established heart disease. Get the full story at our sister site, Drug Delivery Business News. The post Boehringer Ingelheim inks outcomes-based contract with pharmacy benefit manager for diabetes drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - January 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Cardiovascular Diabetes Pharmaceuticals Boehringer Ingelheim Pharmaceuticals Source Type: news

Plasma Volume Changes May Mediate Effects of Empagliflozin
Findings suggest reduced CV mortality risk mediated by effects on markers of plasma volume (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - December 26, 2017 Category: Respiratory Medicine Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Empagliflozin Particularly Effective in'Vulnerable' Diabetes Subgroup Empagliflozin Particularly Effective in'Vulnerable' Diabetes Subgroup
Empagliflozin reduced cardiac death with no signal of increased risk of amputation in patients with type 2 diabetes and PAD in EMPA-REG, with an NNT that was lower than for the trial population as a whole.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 28, 2017 Category: Endocrinology Tags: Cardiology News Source Type: news

No Signal for Amputation With Empagliflozin in EMPA-REG No Signal for Amputation With Empagliflozin in EMPA-REG
A new paper confirms there is no signal for an increased risk of amputation with the SGLT2 inhibitor empagliflozin among patients with type 2 diabetes and CVD in EMPA-REG.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Glyxambi ® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union
Glyxambi ® (empagliflozin/linagliptin) approval recommended by CHMP for adults with type 2 diabetes in the European Union (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Jardiance ® (empagliflozin) to be studied for the treatment of people with chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

New Jardiance ® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New Jardiance ® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 Diabetes: European Commission approves Jardiance ® (empagliflozin)
Type 2 Diabetes: European Commission approves Jardiance ® (empagliflozin) (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials
Type 2 Diabetes: Jardiance ® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union
Type 2 diabetes: Synjardy ® (empagliflozin/metformin hydrochloride) approved in the European Union (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial
Jardiance ® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 27, 2017 Category: Research Source Type: news

AHA 2017 Empagliflozin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 14, 2017 Category: Research Source Type: news

Synjardy XR Extended-release Tablets (Empagliflozin and Metformin Hydrochloride Extended-release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news

More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Jardiance ® (empagliflozin) analysis reinforces established safety profile
An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo. The analysis, which includes the EMPA-REG OUTCOME® trial, was published this month in Advances in Therapy.(1) (Source: World Pharma News)
Source: World Pharma News - July 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Boehringer reports positive safety profile of Jardiance for type 2 diabetes
Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news

June ’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly ’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k … (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news

Jardiance analysis reinforces established safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2017 Category: Research Source Type: news

CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Some see the newly revealed cardiovascular benefits as rendering canagliflozin essentially"interchangeable" with empagliflozin, while others view the amputation signal as a deal breaker.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Boehringer and Lilly to assess empagliflozin for chronic kidney disease
Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney disease. (Source: Drug Development Technology)
Source: Drug Development Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news

Empagliflozin to be studied in chronic kidney disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 12, 2017 Category: Research Source Type: news